Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2025-05-04 Regulatory Filings
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
NTI164 Preclinical Toxicology Studies Update 2 pages 115.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 5 May 2025 from Neurotech International Limited. It reports positive results from preclinical toxicology studies (28-day GLP repeat-dose studies) for their drug NTI164. The content focuses on safety and tolerability findings, supporting future regulatory submissions to FDA, TGA, and EMA. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory update on preclinical study results, not a financial report or earnings release. It is not a report publication announcement since it contains substantive study results and details. The document fits best as a Regulatory Filings (RNS) category, which covers general regulatory announcements and compliance updates that do not fit other specific categories.
2025-05-04 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 336.5KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 28 April 2025 presenting a Quarterly Activities Report for the period ending 31 March 2025. It includes clinical updates, corporate activity, and detailed financial information including an Appendix 4C Quarterly Cash Flow Report, which is a regulatory requirement for Australian listed entities to report quarterly cash flows and related party payments. The document contains substantive financial data and analysis for the quarter, including cash flows from operating, investing, and financing activities, as well as commentary on expenses and cash position. The presence of the Appendix 4C and detailed quarterly financial data confirms this is a comprehensive interim/quarterly report rather than a brief announcement or a simple regulatory filing. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2025
2025-04-27 English
Updated Trading Policy 6 pages 196.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 16 April 2025 from Neurotech International Limited regarding an updated Trading Policy. The content is focused on the company's internal policy on trading securities by Key Management Personnel, insider trading prohibitions, and approval and notification requirements for trading. There is no financial data, earnings information, or report attached or referenced as being published. The document is a regulatory announcement about corporate governance and compliance policy updates rather than a financial report or earnings release. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it contains the full policy text, not just a notice. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-04-15 English
Final Director's Interest Notice 2 pages 154.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares and options held directly or indirectly. The document is a formal notice about a director's shareholdings and interests, which aligns with insider trading or director dealings disclosures. There is no financial performance data, earnings information, or management discussion. The document length is short (2516 characters) and focuses solely on director's securities interests. Therefore, it fits the category of Director's Dealing (DIRS).
2025-04-01 English
Application for quotation of securities - NTI 6 pages 18.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) form used for the application for quotation of securities. It details the issuance and quotation of new securities resulting from the exercise of options or conversion of convertible securities. The document includes specifics such as the number of securities, issue date, and class of securities. It is not a financial report, earnings release, or management discussion, but rather an official announcement related to capital changes and securities quotation. Therefore, the document fits the category of Share Issue/Capital Change announcements.
2025-04-01 English
Secondary Trading Notice 1 page 88.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 2 April 2025, titled 'Secondary Trading Notice Pursuant to Section 708A(5)(e) of the Corporations Act'. It notifies the market about the issuance of ordinary fully paid shares without disclosure under Part 6D.2 of the Corporations Act. The notice confirms compliance with relevant sections of the Corporations Act and states there is no excluded information to disclose. The document is short (2742 characters) and serves as a regulatory compliance announcement related to share issuance, not a full financial report or detailed capital raising document. It does not contain financial statements or detailed analysis, nor is it a report publication announcement. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-04-01 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.